miR-124-3p、lncRNA-MALAT-1在急性髓系白血病中的表达及与临床特征、化疗疗效、预后的关系  

Expression of miR-124-3p,lncRNA-MALAT-1 in Acute Myeloid Leukemia and Its Correlation with Clinical Features,Chemotherapy Efficacy,Prognosis

作　　者：赵冬 杨晓煜[1] ZHAO Dong;YANG Xiaoyu(Department of Clinical Laboratory,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州大学第五附属医院检验科,河南郑州450000

出　　处：《河南医学研究》2025年第5期820-824,共5页Henan Medical Research

基　　金：2020年河南省医学科技攻关计划联合共建项目(LHGJ20200485)。

摘　　要：目的探究长链非编码RNA(lncRNA)-肺腺癌转移相关转录本1(MALAT-1)、微小RNA-124-3p(miR-124-3p)在急性髓系白血病中的表达情况,并探究各指标与患者的临床特征、化疗疗效及预后情况的相关性。方法本研究开展时间为2020年1月至2022年12月,共纳入98例急性髓系白血病患者为研究组,给予标准化疗方案进行治疗,另选取98例健康志愿者为对照组,比较组间miR-124-3p、lncRNA-MALAT-1水平,收集研究组患者的临床资料,并探究各指标及化疗疗效、预后情况与患者miR-124-3p、lncRNA-MALAT-1表达的相关性。结果与对照组相比,研究组miR-124-3p更低,lncRNA-MALAT-1更高(P<0.05)。研究组患者在年龄、髓外病变、性别、血红蛋白、血小板计数、FAB分型方面miR-124-3p及lncRNA-MALAT-1表达水平差异无统计学意义(P>0.05)。研究组中白细胞计数≥30×109 L-1、骨髓原始细胞比率≥70%患者的miR-124-3p水平更低,lncRNA-MALAT-1水平更高(P<0.05)。无效组患者的miR-124-3p水平低于有效组,lncRNA-MALAT-1水平高于有效组(P<0.05)。预后不良组患者的miR-124-3p水平低于预后良好组,lncRNA-MALAT-1水平高于预后良好组(P<0.05)。结论急性髓系白血病患者血中miR-124-3p水平降低,lncRNA-MALAT-1水平升高;miR-124-3p和lncRNA-MALAT-1的表达水平与AML患者的临床特征、化疗疗效和预后情况具有一定关联。Objective To explore the expression level of long non-coding RNA(lncRNA)-metastasis associated lung adenocarcinoma transcript 1(MALAT-1),microRNA-124-3p(miR-124-3p)in acute myeloid leukemia and its correlation with clinical characteristics,chemotherapy efficacy and prognosis.Methods The study was conducted from January 2020 to December 2022.A total of 98 patients with acute myeloid leukemia were included in the study group,given standard chemotherapy regimen for treatment,and 98 healthy volunteers were selected as the control group to compare the levels of miR-124-3p and lncRNA-MALAT-1.The clinical data of the study group were collected,and the correlation of each index,chemotherapy efficacy and prognosis with miR-124-3p and lncRNA-MALAT-1 expression were explored.Results The miR-124-3p level in the study group was lower than that in the control group,the lncRNA-MALAT-1 level was higher than the control group(P<0.05).There was no statistical difference in miR-124-3p,lncRNA-MALAT-1 levels between gender,age,platelet count,hemoglobin,extramedullary lesions,FAB classification(P>0.05).In the study group,the miR-124-3p level of patients with white blood cell count≥30×109 L-1 and bone marrow original cell ratio≥70%was lower,the lncRNA-MALAT-1 level was higher(P<0.05).Patients in the invalid group had lower miR-124-3p levels than those in the effective group,lncRNA-MALAT-1 level than the effective group(P<0.05).Patients in the poor prognosis group had lower miR-124-3p levels than the good prognosis group,lncRNA-MALAT-1 levels were higher than those in the good prognosis group(P<0.05).Conclusion The level of miR-124-3p in blood of patients with acute myeloid leukemia was decreased,and the level of lncRNA-MALAT-1 was increased.The expression levels of miR-124-3p and lncRNA-MALAT-1 are associated with the clinical characteristics,chemotherapy efficacy and prognosis of AML patients.

关 键 词：急性髓系白血病 长链非编码RNA-肺腺癌转移相关转录本1 微小RNA-124-3p 临床特征 化疗 预后 

分 类 号：R446[医药卫生—诊断学]